# A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

> **NCT06873945** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 550 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Ritlecitinib 100 mg
- **DRUG:** Ritlecitinib 50 mg
- **DRUG:** Placebo - 100 mg
- **DRUG:** Placebo - 50 mg

## Key facts

- **NCT ID:** NCT06873945
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-12-21
- **Final completion:** 2026-12-21
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873945, "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06873945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*